Generation Bio Co logo

GBIO

Generation Bio Co

$6.29

Earnings Summary

Net Profits
$-37.93Mn

Highlights

Net Profits:

Generation Bio Co’s net profit fell -23.18% since last year same period to $-37.93Mn in the Q2 2022. On a quarterly growth basis, Generation Bio Co has generated -8.37% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Generation Bio Co post its latest quarter earnings

EPS Estimate Current Quarter
-0.62
EPS Estimate Current Year
-0.62

Highlights

EPS Estimate Current Quarter:

Generation Bio Co’s earning per share (EPS) estimates for the current quarter stand at -0.62 - a -19.23% fall from last quarter’s estimates.

EPS Estimate Current Year:

Generation Bio Co’s earning per share (EPS) estimates for the current year stand at -0.62.

Key Ratios

Key ratios of the Generation Bio Co post its Q2 2022 earnings

Return on Assets (ROA)
-0.18
Return on Equity (ROE)
-0.36
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Generation Bio Co’s return on assets (ROA) stands at -0.18.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Generation Bio Co’s return on equity (ROE) stands at -0.36.

Dividend Per Share (DPS):

Generation Bio Co declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.52
-0.61
-17.31%

Company Information

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is engineered to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company's efficient, scalable manufacturing process supports Generation Bio's mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.

Organisation
Generation Bio Co
Employees
100
Industry
Health Technology